IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Heidi Lopez de Diego et al.

Serial No. 10/568,572 Group Art Unit: 1614

Filed: 14 August 2006 Examiner: N/A

For: SUCCINATE AND MALONATE SALT OF TRANS-4-(IR,3S)-6-CHLORO-3-

PHENYLINDAN-1-YL)-1,2,2-TRIMETHYLPIPERIZINE AND THE USE AS

01 August 2007

A MEDICAMENT

Commissioner for Patents

P.O. Box 1450

Alexandria VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This Supplemental Information Disclosure Statement is submitted under 37 C.F.R. §1.97(c)(2) to supplement the Information Disclosure Statement filed February 16, 2006 and the Supplemental Information Disclosure Statements filed June 26, 2006 and January 31, 2007 in connection with the subject application.

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the eight (8) non-patent literature references that are listed (cited) on the attached Form PTO/SB/08a. A copy of each reference is provided herewith.

It is respectfully requested that the Examiner consider the cited references and that a copy of the enclosed Form PTO/SB/08a be returned indicating that the cited references have been considered. Applicants respectfully request that the Examiner make the cited references of record in the subject application.

Application Serial No. 10/568,572 (Attorney Docket No. 453-US-PCT)
Supplemental Information Disclosure Statement
Dated: 01 August 2007
Page 2 of 2

If a telephone conference would be of assistance in advancing the prosecution of the subject application, applicant's undersigned attorney invites the Examiner to telephone her at the number provided below.

A first Office Action has not been received in connection with the subject application.

Accordingly, pursuant to 37 C.F.R. §1.97(b)(3), applicant believes that the present Supplemental Information Disclosure Statement is timely filed and no fee or certification is due or required.

However, in the event that a first Office Action has been mailed, applicants hereby request consideration of this Information Disclosure Statement, and authorization is hereby given to charge to Deposit Account 503201 ONE HUNDRED AND EIGHTY DOLLARS (\$180.00). Also, authorization is hereby given to charge any underpayment or credit any overpayment to this Deposit Account.

Respectfully submitted,

Margaret M. Buck Registration No. 54,010

Lundbeck Research USA, Inc. 215 College Road Paramus, New Jersey 07652 (201) 261-1331 Ext, 790